Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2014-09-08 Investor Presentation
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 8, 2014, by NeoStem, Inc. It includes a slide presentation as Exhibit 99.1 intended for investor and industry presentations. The text explicitly states that the slide presentation is attached and is used for Regulation FD Disclosure, which typically involves investor presentations or similar communications. The document is relatively short (4234 characters) and primarily serves to furnish a presentation rather than provide detailed financial statements or analysis. According to the classification rules, such a document with a slide presentation attached and used for investor communication fits best under the category 'Investor Presentation (IP)'.
2014-09-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is identified as a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (2105 characters) and does not contain financial statements or detailed financial data, but rather appears to be related to shareholder voting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2014-08-29 English
DEF 14A
Proxy Solicitation & Information Statement
2014-08-29 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-08-28 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, related to the 2014 Annual Meeting of Stockholders of NeoStem, Inc. It includes detailed information about the meeting agenda, proposals to be voted on, voting procedures, record dates, and other shareholder meeting logistics. The document is not a report of voting results, nor is it an announcement of a report publication. It is not an annual report, earnings release, or any other financial report. It is a solicitation of proxies and information provided to shareholders to inform their voting decisions at the Annual Meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a brief notice or announcement. Confidence is high due to the clear identification of the document as a Schedule 14A Proxy Statement and the detailed content consistent with proxy materials.
2014-08-19 English
OWNERSHIP DOCUMENT
Director's Dealing
2014-08-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.